Treatments for metastatic melanoma: synthesis of evidence from randomized trials
P Lui, R Cashin, M Machado, M Hemels… - Cancer treatment …, 2007 - Elsevier
BACKGROUND: Advanced melanomas (non-resectable Stage-III/IV) are fatal, with few
effective treatments. It remains unclear if other drugs offer improvements over the standard …
effective treatments. It remains unclear if other drugs offer improvements over the standard …
Treatment for metastatic malignant melanoma: old drugs and new strategies
R Mouawad, M Sebert, J Michels, J Bloch… - Critical reviews in …, 2010 - Elsevier
The number of melanoma cases worldwide is increasing faster than any other cancer and
remains one of the most treatment-refractory malignancies. Despite decades of clinical trials …
remains one of the most treatment-refractory malignancies. Despite decades of clinical trials …
[HTML][HTML] Metastatic melanoma–a review of current and future drugs
TR Velho - Drugs in context, 2012 - ncbi.nlm.nih.gov
Background: Melanoma is one of the most aggressive cancers, and it is estimated that
76,250 men and women will be diagnosed with melanoma of the skin in the USA in 2012 …
76,250 men and women will be diagnosed with melanoma of the skin in the USA in 2012 …
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
AMM Eggermont, JM Kirkwood - European journal of cancer, 2004 - Elsevier
Since dacarbazine was approved for treating metastatic melanoma in the 1970s, numerous
studies have evaluated whether different schedules and dacarbazine-based combinations …
studies have evaluated whether different schedules and dacarbazine-based combinations …
Dacarbazine combined targeted therapy versus dacarbazine alone in patients with malignant melanoma: a meta-analysis
G Jiang, RH Li, C Sun, YQ Liu, JN Zheng - PLoS One, 2014 - journals.plos.org
Background Malignant melanoma is the most aggressive and deadly form of skin cancer.
Dacarbazine (DTIC) has been the approved first-line treatment for metastatic melanoma in …
Dacarbazine (DTIC) has been the approved first-line treatment for metastatic melanoma in …
Treatment of metastatic malignant melanoma
E Atallah, L Flaherty - Current treatment options in oncology, 2005 - Springer
Opinion statement The rapid increase in incidence of malignant melanoma has not been
associated with better therapeutic options over the years. Single-agent chemotherapy or …
associated with better therapeutic options over the years. Single-agent chemotherapy or …
Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-α) in metastatic melanoma
AM Young, J Marsden, A Goodman, A Burton, JA Dunn - Clinical Oncology, 2001 - Elsevier
Dacarbazine (DTIC) has been the mainstay of chemotherapy for metastatic melanoma for
over two decades, but only 15%–20% of patients respond and benefit is usually transient …
over two decades, but only 15%–20% of patients respond and benefit is usually transient …
Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized …
M Huncharek, JF Caubet, R McGarry - Melanoma research, 2001 - journals.lww.com
It is currently unclear whether any combination therapy for the treatment of metastatic
melanoma is superior to standard single-agent dacarbazine (DTIC) in terms of tumour …
melanoma is superior to standard single-agent dacarbazine (DTIC) in terms of tumour …
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials
Background Recent phase 3 trials have shown an overall survival benefit in metastatic
melanoma. We aimed to assess whether progression-free survival (PFS) could be regarded …
melanoma. We aimed to assess whether progression-free survival (PFS) could be regarded …
Systemic treatments for metastatic cutaneous melanoma
T Crosby, R Fish, B Coles, M Mason… - Cochrane Database …, 1996 - cochranelibrary.com
Background Systemic therapies for metastatic cutaneous melanoma, the most aggressive of
all skin cancers, remain disappointing. Few lasting remissions are achieved and the …
all skin cancers, remain disappointing. Few lasting remissions are achieved and the …